Protalix is a commercial stage biopharmaceutical company focused on the development and commercialization of proprietary recombinant therapeutic proteins that target rare genetic diseases with unmet medical needs. Protalix now has two US FDA approved Enzyme Replacement Therapies for the treatment of Gaucher and Fabry diseases which demonstrates its expertise and capabilities required to successfully bring a complex therapeutic product through the full clinical and regulatory approval cycle. These two programs are supported by commercial partnerships with Pfizer and Chiesi Farmaceutici. Going forward, Protalix will continue to leverage internal capabilities as well as actively engage in external partnerships and in-licensing to grow and expand a pipeline of innovative therapeutics to treat genetic and non-genetic rare diseases.